3-(硬脂酰氧基)-4-(三甲基铵基)丁酸酯 | 1976-27-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 3-(硬脂酰氧基)-4-(三甲基铵基)丁酸酯
• 中文别名: 硬脂酰肉碱
• 英文名称: Acylcarnitine C18:0
• 英文别名: 3-octadecanoyloxy-4-(trimethylazaniumyl)butanoate
• CAS: 1976-27-8
• 化学式: C25H49NO4
• 分子量: 427.7
• InChiKey: FNPHNLNTJNMAEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.8
• 重原子数：
  30
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] STABLE INDOLE-3-PROPIONATE SALTS OF S-ADENOSYL-L-METHIONINE<br/>[FR] SELS D'INDOLE-3-PROPIONATE STABLES DE LA S-ADÉNOSYL-L-MÉTHIONINE
  申请人：HEBERT SAM E LLC

  公开号：WO2014113609A1

  公开（公告）日：2014-07-24

  Stable indole-3-propionic acid salts of S-adenosyl-L-methionine, or a pharmaceutically acceptable salt thereof, are disclosed, as well as pharmaceutical compositions comprising the indole-3-propionic acid salts, methods of using the indole-3-propionic acid salts and processes for making same.

  本发明公开了稳定的S-腺苷甲硫氨酸的吲哚-3-丙酸盐，或其药用可接受的盐，以及包含吲哚-3-丙酸盐的药物组合物，使用吲哚-3-丙酸盐的方法和制备方法。
• METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION
  申请人：T3D Therapeutics, Inc.

  公开号：US20210369680A1

  公开（公告）日：2021-12-02

  This disclosure describes the use of indane acetic acid derivatives which are PPAR agonists, including PPAR delta, PPAR gamma, and dual PPAR delta and gamma agonists, and which penetrate the blood brain barrier to achieve effective brain to plasma drug levels at non-toxic doses, for the treatment of betacoronavirus diseases, such as COVID-19 and COVID-19 related co-morbid diseases, including Acute Respiratory Distress and CNS disorders, such as delirium and cognitive impairment.

  本公开说明了使用indane乙酸衍生物作为PPAR激动剂，包括PPAR delta，PPAR gamma和双重PPAR delta和gamma激动剂，这些激动剂穿过血脑屏障，在非毒性剂量下实现有效的脑血浆药物水平，用于治疗β冠状病毒疾病，如COVID-19和COVID-19相关的共病疾病，包括急性呼吸窘迫和中枢神经系统疾病，如谵妄和认知障碍。
• [EN] CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF<br/>[FR] PRODUIT PHARMACEUTIQUE CRISTALLIN ET SES PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：SARCODE CORP

  公开号：WO2009139817A2

  公开（公告）日：2009-11-19

  Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.

  本发明揭示了一种化合物I的新颖结晶多态形式A、B、C、D和E，该化合物已被发现是LFA-1的有效抑制剂。本发明还揭示了制备方法以及在治疗LFA-1介导的疾病中使用该化合物的方法。
• [EN] CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF<br/>[FR] AGENT PHARMACEUTIQUE CRISTALLIN ET PROCÉDÉS DE PRÉPARATION ET UTILISATION DE CELUI-CI
  申请人：SARCODE CORP

  公开号：WO2011050175A1

  公开（公告）日：2011-04-28

  Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula (I), which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.

  本发明揭示了化合物I的新型晶体多态形式A、B、C、D和E，该化合物已被发现是LFA-1的有效抑制剂。本发明还揭示了其制备方法以及在治疗LFA-1介导的疾病中的用途。
• Crystalline Pharmaceutical and Methods of Preparation and Use Thereof
  申请人：SARcode Bioscience, Inc.

  公开号：US20130150585A1

  公开（公告）日：2013-06-13

  Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.

  本发明揭示了化合物I的新晶态多形式，包括A、B、C、D和E形式，该化合物已被发现是一种有效的LFA-1抑制剂。本发明还揭示了制备方法以及在治疗LFA-1介导的疾病中使用该化合物的用途。